Profiling Alzheimer's Disease Biomarkers in Blood Serum
November 20, 2014
Alzheimer's Disease (AD) is one of the most common neurodenerative disorders worldwide. It is a progressive disorder characterized by gradual loss of mental ability associated with the death of brain cells, and is diagnosed using a combination of physical, neurological, and laboratory tests. Although there are no curative treatments available, early treatment can reduce the rate of the disease progression. Scientists from the University of Huelva and the Neurological Service from the Hospital Juan Ramon Jim?nez in Spain, began collaborating four years ago to develop new strategies to identify biomarkers that could be used to speed up diagnosis of the disease. In a new study published in the journal Electrophoresis, the team present a metabolomics approach based on ultrafiltration followed by capillary electrophoresis coupled with mass spectrometry (CE–ESI–MS) for the fingerprinting of polar metabolites in blood serum.